HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Katzmann, J. A. Search for Related Content PubMed PubMed Citation Articles by Katzmann, J. A.

Serum Free Light Chain Specificity and Sensitivity: A Reality Check

Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905, E-mail Katzmann.Jerry@mayo.edu

The first 20% of the full text of this article appears below.

In 2001, a commercial test consisting of 2 separate measurements to quantify and free light chains (FLCs) was reported in Clinical Chemistry(1). The antisera specificities in this assay were reported to be 10 000-fold higher for FLCs than for light chains bound to immunoglobulin heavy chains.

FLCs were thought to be associated with imbalances in heavy and light chain production in monoclonal plasma cell populations, and their quantifiability in the presence of the bulk of serum immunoglobulin opened new opportunities for characterizing plasma cell proliferation disorders. The reference interval for polyclonal FLCs was documented, and the reference interval for the free light chain -to- (FLC K/L) ratio was demonstrated to be a sensitive indicator for excess (e.g., clonal) FLC production(1)(2). The gold standard for detection of monoclonal proteins is immunofixation electrophoresis (IFE). Several retrospective studies, however, showed that serum FLC had substantially higher detection limits than serum and urine IFE for diagnosis of the monoclonal light chain diseases of primary light-chain amyloidosis(3)(4) and light chain deposition disease(2), as well as nonsecretory multiple myeloma(5). This increase in diagnostic detection limit for this subset of monoclonal gammopathies indicates that the serum FLC assay is a natural addition to serum and urine IFE for diagnostic testing in the monoclonal gammopathies.

The serum FLC assay specificity for the monoclonal plasma cell proliferative disorders resides . . . [Full Text of this Article]

The following articles in journals at HighWire Press have cited this article:

				F.-U. Sack, A. Kristen, H. Goldschmidt, P. A. Schnabel, T. Dengler, A. Koch, and M. Karck Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 257 - 262. [Abstract] [Full Text] [PDF]

				E. S.K. Ma and E. T.K. Lee A Case of IgM Paraproteinemia in Which Serum Free Light Chain Values Were Within Reference Intervals Clin. Chem., February 1, 2007; 53(2): 362 - 363. [Full Text] [PDF]